Colangiocarcinoma em cão: Relato de caso
Resumo
O colangiocarcinoma é uma neoplasia hepática maligna com prognóstico reservado. Este relato descreve o caso de um cão da raça Shih Tzu, macho, castrado, de 10 anos, atendido em um hospital veterinário com sinais gastrintestinais. Exames laboratoriais revelaram elevação das enzimas hepáticas e a ultrassonografia inicial revelou uma área nodular no fígado. A tomografia computadorizada mostrou uma formação ovalada e heterogênea no lobo hepático, sugerindo neoplasia e hiperplasia hepática em outras áreas. O cão foi submetido à lobectomia, e a análise histopatológica confirmou colangiocarcinoma pouco diferenciado. O tratamento quimioterápico inicial com ciclofosfamida foi ajustado com base nos resultados do painel Oncomapa, que apontou alta expressão de genes relacionados à progressão tumoral e indicou o uso de toceranib como terapia-alvo. A resposta positiva à terapia personalizada, baseada no perfil molecular do tumor, resultou em uma sobrevida acima da média relatada na literatura, demonstrando o potencial do tratamento individualizado no manejo do colangiocarcinoma em cães.
Palavras-chave
Referências
ASSAWARACHAN, S. N.; MANEESAAY, P.; THENGCHAISRI, N. A descriptive study of the histopathologic and biochemical liver test abnormalities in dogs with liver disease in Thailand. Canadian journal of veterinary research, v. 84, n. 3, p. 217-224, 2020.
BALKMAN, C. Hepatobiliary neoplasia in dogs and cats. Veterinary Clinics: Small Animal Practice, v. 39, n. 3, p. 617-625, 2009.
BEAUFRÈRE, A.; CALDERARO, J.; PARADIS, V. Combined hepatocellular- cholangiocarcinoma: an update. Journal of hepatology, v. 74, n. 5, p. 1212-1224, 2021.
BUISHAND, F. O. Current trends in diagnosis, treatment and prognosis of canine insulinoma. Veterinary Sciences, v. 9, n. 10, p. 540, 2022.
BURTI, S. et al. Contrast-enhanced ultrasound features of malignant focal liver masses in dogs. Scientific Reports, v. 10, n. 1, p. 6076, 2020.
CHARLES, J. A. et al. Morphological classification of neoplastic disorders of the canine and feline liver. In: Standards for clinical and histological diagnosis of canine and feline liver diseases. WSAVA Liver Standardization Group. Philadelphia: Saunders Elsevier, p. 117-24, 2006.
CHENEY, D. M. et al. Ultrasonographic and CT accuracy in localising surgical‐or necropsy‐ confirmed solitary hepatic masses in dogs. Journal of Small Animal Practice, v. 60, n. 5, p. 274- 279, 2019.
CHOI, L. et al. Adjuvant therapy with toceranib for hepatocellular carcinoma and cholangiocarcinoma in a Pomeranian. Veterinární medicína, v. 68, n. 2, p. 83, 2023.
CULLEN, J. M. Tumors of the liver and gallbladder. Tumors in domestic animals, p. 602- 631, 2016.
DOMINGUEZ, P.A. et al. Combined gemcitabine and carboplatin therapy for carcinomas in dogs. Journal of veterinary internal medicine, v. 23, n. 1, p. 130-137, 2009.
FLESNER, B.K. et al. Long-term survival and glycemic control with toceranib phosphate and prednisone for a metastatic canine insulinoma. Journal of the American Animal Hospital Association, v. 55, n. 1, p. e551-05, 2019.
FONTES, G.S. et al. Thromboelastographic results and hypercoagulability in dogs with surgically treated hepatocellular adenoma and carcinoma: A Veterinary Society of Surgical Oncology prospective study. Veterinary and Comparative Oncology, v. 21, n. 4, p. 616-622, 2023.
FOSKETT, A. et al. Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer. Veterinary Medicine: Research and Reports, p. 97-102, 2017.
HOU, Helei; SUN, Dantong; ZHANG, Xiaochun. The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer cell international, v. 19, n. 1, p. 216, 2019.
KINSEY, J. R. et al. Factors associated with long-term survival in dogs undergoing liver lobectomy as treatment for liver tumors. The Canadian Veterinary Journal, v. 56, n. 6, p. 598, 2015.
LEONG, A. et al. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology, v. 33, n. 4, p. 318-324, 1998.
LEYVA, F.J. et al. Histopathologic characteristics of biopsies from dogs undergoing surgery with concurrent gross splenic and hepatic masses: 125 cases (2012–2016). BMC research notes, v. 11, p. 1-5, 2018.
LINDEN, Daniel S. et al. Outcomes and prognostic variables associated with central division hepatic lobectomies: 61 dogs. Veterinary Surgery, v. 48, n. 3, p. 309-314, 2019.
LIPTAK, J.M. et al. Massive hepatocellular carcinoma in dogs: 48 cases (1992– 2002). Journal of the American Veterinary Medical Association, v. 225, n. 8, p. 1225-1230, 2004.
MARCONATO, L. et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma: preliminary toxicity and activity data in dogs. Cancers, v. 12, n. 5, p. 1272, 2020.
MONTE, A.S. et al. A Importância da tomografia computadorizada para o diagnóstico de neoplasias: relato de caso. Revista Brasileira de Higiene e Sanidade Animal, v. 18, n. 1, p. 1- 6, 2024.
MOYER, J. et al. Factors associated with survival in dogs with a histopathological diagnosis of hepatocellular carcinoma: 94 cases (2007–2018). Open Veterinary Journal, v. 11, n. 1, p. 144-153, 2021.
RAMOS-VARA, J. A.; MILLER, M. A.; JOHNSON, G.C. Immunohistochemical characterization of canine hyperplastic hepatic lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to cytokeratin 7. Veterinary pathology, v. 38, n. 6, p. 636-643, 2001.
URFER, Silvan R. et al. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. Geroscience, v. 39, p. 117-127, 2017.
WORMER, C.; REETZ, J.A.; GIUFFRIDA, M. A. Diagnostic accuracy of ultrasound to predict the location of solitary hepatic masses in dogs. Veterinary surgery, v. 45, n. 2, p. 208-213, 2016.
Apontamentos
- Não há apontamentos.
Visitas